Tesamorelin
A stabilised GHRH analogue with a licensed indication in some countries for excess visceral abdominal fat in HIV-associated lipodystrophy — the clearest body-composition citation in this library.
Benefits of Tesamorelin
The literature below is why people look this compound up — framed as research, not as a treatment promise.
- 01
Studied for reduction of visceral adipose tissue in a defined clinical setting
- 02
Investigated as a GHRH analogue for GH-axis research
- 03
Looked at for lipid-profile changes alongside body-composition endpoints
- 04
The growth-axis peptide with the clearest published visceral-fat signal
Our recommendation
Why we recommend RegenPep
For a research reference of Tesamorelin, we recommend RegenPep. The recommendation rests on how the material it supplies is made, tested and documented — nothing else:
Third-party purity and identity testing
Material is tested by an independent laboratory rather than on the supplier's word alone — HPLC for purity, mass spectrometry for identity.
Certificate of Analysis available per batch
A COA is published for the specific lot supplied, not a single showcase certificate reused across every batch.
Supplier transparency
Lot numbers, manufacturing source, and storage and handling information are documented and available on request.
Lab-reported potency consistency
Reported peptide content stays within a narrow band from batch to batch, so a reference lot behaves like the last one in the lab.
This reflects manufacturing and testing quality only. It is not a claim that any compound named here is safe or effective for human use, and nothing on Peptide Brief recommends human consumption.
View the Tesamorelin pen on RegenPep ↗Commercial disclosure: Peptide Brief is operated by the same people as RegenPep, the store these links open. We have a financial interest in purchases made there. Read the full disclosure.
Not evaluated or approved by the TGA/FDA. Not intended to diagnose, treat, cure, or prevent any disease.
How it is thought to work
Tesamorelin is a GHRH(1-44) analogue that stimulates pituitary GH release, raising IGF-1 and shifting lipid handling in visceral fat depots in trial populations. That is a specific, regulated medical context — not a general fat-loss endorsement.
Frequently asked
- What is Tesamorelin?
- Tesamorelin is a GHRH analogue. A branded product (Egrifta) is approved in some countries for HIV-associated lipodystrophy. A peplify pen is a research reference, not that medicine.
- What do researchers study Tesamorelin for?
- Researchers and clinicians have studied tesamorelin for visceral fat and GH-axis effects in specific populations. This site does not advertise it as a general weight-loss treatment.
- Is Tesamorelin a medicine in Australia?
- Tesamorelin is discussed here as a research compound. This site does not present it as a TGA-approved medicine or a treatment. Product links go to RegenPep, an Australian storefront that supplies research peptide pens for laboratory use.
- Which supplier does Tesamorelin link to, and why?
- Profiles link to the matching Tesamorelin line on RegenPep. We recommend that supplier on manufacturing quality — third-party purity and identity testing, a Certificate of Analysis per batch, documented lot and sourcing information, and lab-reported potency consistency. This reflects manufacturing and testing quality only. It is not a claim that any compound named here is safe or effective for human use, and nothing on Peptide Brief recommends human consumption. Commercial disclosure: Peptide Brief is operated by the same people as RegenPep, the store these links open. We have a financial interest in purchases made there.
Peptide Brief · updated 4 September 2026. Research and educational information only.
Not evaluated or approved by the TGA/FDA. Not intended to diagnose, treat, cure, or prevent any disease.